PGEN · CIK 0001356090
What Precigen, Inc. told the SEC could break it.
Precigen's register is that of a biotech in its first commercial year, riding on a single product. It expects future revenue to come primarily from Papzimeos, an RRP immunotherapy that won FDA approval and launched in the fourth quarter of 2025, concentrating its fortunes on that one newly launched therapy — while its finances are strained, having received a Nasdaq bid-price deficiency (its stock fell below $1.00) and leaning on dilutive financing including 8% convertible preferred with paid-in-kind dividends and warrants, amid ongoing operating losses. And as a commercial drug maker, it's exposed to IRA drug-pricing reforms — Medicare price negotiation and inflation rebates — that could pressure what it can charge.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Liquidity & debt
- Nasdaq bid-price deficiency & dilutive financingmedium
Precigen received a Nasdaq bid-price deficiency (stock below $1.00; 180-day cure to April 30, 2025) and relies on dilutive financing — 8% Series A convertible preferred with PIK dividends and warrants for ~52.7M shares at $0.75 — amid ongoing operating losses.
“we were provided an initial period of 180 calendar days, or until April 30, 2025, to regain compliance. To regain compliance, the bid price of our common stock must close at $1.00 per share or more for a minimum of ten consecutive business days during such 180-day compliance period.”
SEC filing →As of 2026
Other disclosures
- single-product dependence (Papzimeos)medium
Precigen expects future revenue to come primarily from a single product, Papzimeos (RRP immunotherapy, FDA-approved and launched Q4 2025), concentrating its commercial fortunes on one newly launched therapy in its first commercial year.
“we anticipate our future revenue to primarily be generated from Papzimeos product sales.”
SEC filing →As of 2026
Regulatory & policy
- IRA / Medicare drug-price negotiation & rebatesmedium
As a commercial drug manufacturer, Precigen is exposed to IRA drug-pricing reforms — Medicare price negotiation (subject to a cap) and inflation rebates under Medicare Parts B and D — plus elimination of the Medicaid rebate cap and ACA changes.
“the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch